Insights

Section 1: The 505(b)(2) Value Proposition — Pricing Incremental Innovation 1.1 Why the Pathway Exists and What It Actually Does […]

Why Standard Patent Intelligence Is Failing You The patent cliff is no longer the right mental model. For two decades,

University Technology Transfer Offices (TTOs) sit at one of the most commercially consequential intersections in American innovation: the point where

1. Why ‘Inactive’ Is a Dangerous Word: The Strategic Case for Excipient Scrutiny The Myth That Costs Billions The word

Section 1: The Strategic Landscape: Why Patent Intelligence Has Become a Core Payer Competency The Formulary Has Become a Battlefield

1. What Paragraph IV Actually Is — and Why It Matters A Paragraph IV certification is a formal legal assertion

I. Executive Summary Clinical trial velocity is not a measure of how fast a sponsor pushes a molecule through regulatory

How to turn patent data into competitive advantage — from prior art to pipeline defense to biosimilar market entry Why

A deep-dive reference for pharma/biotech IP teams, R&D leads, portfolio managers, and institutional investors who need forecasts that hold up